NCT05510089

Etoposide+Cytarabine+PEG-rhG-CSF for Hematopoietic Stem Cell Mobilization in Patients With Hematological Malignancies

Prospective, Single-arm, Multicenter Exploratory Clinical Study of the Combination of Etoposide, Cytarabine and PEG-rhG-CSF (EAP Regimen) on Hematopoietic Stem Cell Mobilization in Poor Mobilization Patients With Hematological Malignancies

• Status: Unknown
• Phase: N/A
• Study type: Interventional
• Enrollment: 62 (estimated)
• Sponsor: The Affiliated People's Hospital of Ningbo University · Other Government
• Sex: All
• Age: 18 Years – 75 Years
• Healthy volunteers: Not accepted

Summary

This is a single-arm, multicenter, exploratory clinical study to evaluate the safety and efficacy of the combination of etoposide, cytarabine and PEG-rhG-CSF (EAP regimen) on hematopoietic stem cell mobilization in poor mobilization patients with hematological malignancies. All eligible patients will receive EAP regimen treatment, then the number of CD34+ cells and white blood cells will be monitoring. When the collection standard is met, hematopoietic stem cell collection will be started.

Conditions

• Hematological Malignancy

Interventions

Type	Name	Description
DRUG	Etoposide	D1\~D2: 75mg/m\^2
DRUG	Cytarabine	D1\~D2: 300mg/m\^2, q12h
DRUG	PEG-rhG-CSF	D6: 6mg

Timeline

• Start date: 2022-09-01
• Primary completion: 2024-05-31
• Completion: 2024-12-31
• First posted: 2022-08-22
• Last updated: 2023-10-10

Locations

12 sites across 1 country: China